Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

As the European Lung Cancer Congress prepares to convene in Copenhagen, BioNTech SE is shifting investor focus toward its expanding oncology portfolio. New clinical data for its antibody-drug ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 10 (Reuters) - BioNTech's two co-founders and leading executives will ...

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech (NasdaqGS:BNTX) cofounders Ugur Sahin and Özlem Türeci are leaving their roles as CEO and Chief Medical Officer.

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to ...

Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...